why choose us

Clinical Trials Search

Showing 17,110 of 132,963 result(s)
A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM)

Status: Completed

Condition: Idiopathic Inflammatory Myositis

Interventions: Participants will be administered daxdilimab by subcutaneous (SC) injection

Date: 2022-12-20

OMAR Opioid Use Disorder

Status: Completed

Condition: Healthy Control

Interventions: For each [11C]OMAR PET scan, up to 20 mCi of [11C]OMAR will be administered.

Date: 2022-12-20

The Feasibility, Usability, and Acceptability of Using the Oculus™ Virtual Reality Gaming Technology in Stroke Survivors for Upper Extremity and Cognitive Rehabilitation

Status: Completed

Condition: Stroke

Interventions: During the first visit, the Oculus headset will be placed on the stroke survivor's head and demonstrate how to use the headset.
participant

Date: 2022-12-20

Daratumumab in Primary Antiphospholipid Syndrome

Status: Completed

Condition: Autoimmune Disorders

Interventions: Participants will receive 4 mg;kg of intravenous (IV) daratumumab administered weekly for 8 doses (weeks 0 through 7).
Post-treatment follow

Date: 2022-12-20

A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma

Status: Completed

Condition: Recurrent High Grade Glioma

Interventions: Patients will take the PCI-24781;Abexinostat on days 1-4, 8-11, 15-18, and 22-25 of each 28-day cycle.

Date: 2022-12-20

Oximeters and Skin Pigment: Impact of Skin Pigmentation on Accuracy of Pulse Oximetry

Status: Completed

Condition: Hypoxemia

Interventions: Several pulse oximeter will be place on patients fingers a few minutes before arterial blood gases.
SpO2 will be recorded during that time and up

Date: 2022-12-20

Efficacy and Safety of Lonigutamab in Subjects With Thyroid Eye Disease (TED)

Status: Completed

Condition: Thyroid Eye Disease

Interventions: subcutaneous injection

Date: 2022-12-20

Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus

Status: ACTIVE_NOT_RECRUITING

Condition: Obesity

Interventions: Participants will receive AMG 133 through 48 weeks.

Date: 2022-12-20

GRETeL: Tumor Response to Standard Radiotherapy and TMZ Patients With GBM

Status: Completed

Condition: Glioblastoma

Interventions:

Date: 2022-12-20